Vanda Pharmaceuticals (VNDA) News Today $4.44 +0.13 (+3.02%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VNDA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Insider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Purchases 20,000 Shares of StockMay 20 at 5:17 AM | insidertrades.comInsider Buying: Mihael Polymeropoulos Acquires 20,000 Shares of Vanda Pharmaceuticals Inc (VNDA)May 20 at 2:34 AM | gurufocus.comHC Wainwright Issues Pessimistic Estimate for VNDA EarningsVanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - HC Wainwright decreased their Q2 2025 EPS estimates for Vanda Pharmaceuticals in a report issued on Wednesday, May 14th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of (May 18 at 7:53 AM | marketbeat.comJacobs Levy Equity Management Inc. Has $2.26 Million Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Jacobs Levy Equity Management Inc. lowered its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 67.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 470,726 shares of the biopharmaceuticalMay 18 at 4:35 AM | marketbeat.comQ2 EPS Forecast for Vanda Pharmaceuticals Cut by AnalystMay 18 at 1:27 AM | americanbankingnews.comVanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit ...May 16, 2025 | gurufocus.comVanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025May 16, 2025 | prnewswire.comVanda Pharmaceuticals' (VNDA) "Overweight" Rating Reiterated at Cantor FitzgeraldMay 16, 2025 | americanbankingnews.comVanda Pharmaceuticals (VNDA) Receives Overweight Rating from Cantor Fitzgerald | VNDA Stock NewsMay 14, 2025 | gurufocus.comVanda Pharmaceuticals (VNDA) Projected to Transform with Overweight Rating | VNDA Stock NewsMay 14, 2025 | gurufocus.comBridgeway Capital Management LLC Has $796,000 Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Bridgeway Capital Management LLC decreased its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 60.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 166,200 shares of the biopharmaceutical company's stock after selling 25May 14, 2025 | marketbeat.comVNDA FY2025 EPS Estimate Lowered by Cantor FitzgeraldVanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Cantor Fitzgerald dropped their FY2025 earnings estimates for Vanda Pharmaceuticals in a research note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will posMay 13, 2025 | marketbeat.comAnalysts Set Expectations for VNDA FY2025 EarningsMay 13, 2025 | americanbankingnews.comDimensional Fund Advisors LP Grows Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Dimensional Fund Advisors LP raised its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 10.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,488,519 shares of the biopharmaceutical compMay 12, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Acquires New Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Schonfeld Strategic Advisors LLC bought a new position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 270,541 shares of the biopharmaceutical company's stockMay 10, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday.May 9, 2025 | marketbeat.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 9, 2025 | finanznachrichten.deVanda Pharmaceuticals’ Earnings Call: Growth Amid ChallengesMay 8, 2025 | tipranks.comVanda Pharmaceuticals Inc (VNDA) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Rising ...May 8, 2025 | finance.yahoo.comVanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comVanda Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 7, 2025 | prnewswire.comFDA accepts Vanda’s new antipsychotic drug for reviewMay 7, 2025 | uk.investing.comA Glimpse of Vanda Pharma's Earnings PotentialMay 6, 2025 | benzinga.comVanda Pharmaceuticals Q1 Earnings PreviewMay 6, 2025 | msn.comMarshall Wace LLP Purchases Shares of 80,800 Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Marshall Wace LLP acquired a new position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 80,800 shares of the biopharmaceutical company's stock,May 6, 2025 | marketbeat.comVanda Pharmaceuticals Inc.: Vanda Announces Bysanti NDA Filing; FDA Decision Expected in Early 2026May 5, 2025 | finanznachrichten.deVanda Pharmaceuticals (VNDA) Expected to Announce Earnings on WednesdayVanda Pharmaceuticals (NASDAQ:VNDA) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-7-vanda-pharmaceuticals-inc-stock/)May 5, 2025 | marketbeat.comVanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026May 5, 2025 | prnewswire.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Up 21.4% in AprilVanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 4,880,000 shares, an increase of 21.4% from the March 31st total of 4,020,000 shares. Based on an average daily volume of 663,100 shares, the short-interest ratio is currently 7.4 days. Currently, 9.0% of the company's stock are short sold.May 5, 2025 | marketbeat.com254,845 Shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Bought by Susquehanna Fundamental Investments LLCSusquehanna Fundamental Investments LLC bought a new position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 254,845 shares of the biopharmaceuticalMay 4, 2025 | marketbeat.comVanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025May 2, 2025 | prnewswire.comJPMorgan Chase & Co. Purchases 175,019 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)JPMorgan Chase & Co. grew its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 108.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 335,741 shares of the biopApril 28, 2025 | marketbeat.com64,000 Shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Acquired by Empire Financial Management Company LLCEmpire Financial Management Company LLC purchased a new position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 64,000 shares of the biopharmaceutical companApril 27, 2025 | marketbeat.comVanda says FDA ‘unlawfully’ delaying hearingApril 25, 2025 | markets.businessinsider.comVanda claims FDA 'unlawfully' delays hearing request on tradipitant decisionApril 23, 2025 | msn.comVanda Pharmaceuticals (VNDA) Criticizes FDA Over Tradipitant Hearing Delay | VNDA Stock NewsApril 23, 2025 | gurufocus.comFDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDAApril 23, 2025 | prnewswire.comVanguard Group Inc. Has $16.80 Million Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Vanguard Group Inc. lowered its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 3.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,506,287 shares of the biopharmaceutical company's stock afApril 19, 2025 | marketbeat.comExodusPoint Capital Management LP Reduces Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)ExodusPoint Capital Management LP reduced its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 74.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,506 shares of the biopharmaApril 16, 2025 | marketbeat.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Renaissance Technologies LLCRenaissance Technologies LLC decreased its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 3.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,853,799 shares of the biopharmaceutical company's stockApril 15, 2025 | marketbeat.com115,000 Shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Purchased by Norges BankNorges Bank acquired a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 115,000 shares of the biopharmaceutical compaApril 14, 2025 | marketbeat.comVanda Pharmaceuticals: Financials Are Great, But Market Reaction Is ConfusingApril 7, 2025 | seekingalpha.comVanda Pharmaceuticals Announces Presentation at 2025 AAN Annual MeetingApril 7, 2025 | prnewswire.com135,400 Shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Bought by KLP Kapitalforvaltning ASKLP Kapitalforvaltning AS bought a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 135,400 shares of the biopharmApril 3, 2025 | marketbeat.comVanda Pharma Submits NDA For Bysanti To FDA To Treat Acute Bipolar I Disorder And SchizophreniaApril 2, 2025 | nasdaq.comVanda Pharmaceuticals' (VNDA) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a research note on Tuesday.April 2, 2025 | marketbeat.comVanda Pharmaceuticals submits NDA to FDA for BysantiMarch 31, 2025 | markets.businessinsider.comVanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and SchizophreniaMarch 31, 2025 | prnewswire.comVanda Pharmaceuticals’ New Drug Application Accepted by FDAMarch 17, 2025 | tipranks.comVNDA Vanda Pharmaceuticals Inc.March 15, 2025 | seekingalpha.com Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address VNDA Media Mentions By Week VNDA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VNDA News Sentiment▼0.270.65▲Average Medical News Sentiment VNDA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VNDA Articles This Week▼244▲VNDA Articles Average Week Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Geron News Today Regulus Therapeutics News Today Zenas Biopharma News Today Verastem News Today Myriad Genetics News Today Emergent BioSolutions News Today Rigel Pharmaceuticals News Today XOMA News Today Codexis News Today Lexicon Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VNDA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VNDA Stock Free VNDA Stock Alerts